Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis - A randomized cross-over study

BMC Nephrology

Volumn 16, Issue 1, 2015, Pages

  Gamboa, Jorge L ^a   Pretorius, Mias ^a   Sprinkel, Katie C ^a   Brown, Nancy J ^a   Ikizler, T Alp ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin receptor blocker; Asymmetric dimethylarginine; Hemodialysis

Indexed keywords

BRADYKININ; BRADYKININ B3 RECEPTOR; BRADYKININ RECEPTOR; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE; N(G),N(G) DIMETHYLARGININE; PLACEBO; RAMIPRIL; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ARGININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; N,N-DIMETHYLARGININE;

A549 CELL LINE; ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; END STAGE RENAL DISEASE; ENZYME INHIBITION; FEMALE; HEMODIALYSIS; HUMAN; HUMAN CELL; MAINTENANCE HEMODIALYSIS; MAINTENANCE THERAPY; MALE; MIDDLE AGED; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; ANALOGS AND DERIVATIVES; BLOOD; CELL LINE; DRUG EFFECTS; KIDNEY FAILURE, CHRONIC; METABOLISM; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARGININE; BRADYKININ; CELL LINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RAMIPRIL; RENAL DIALYSIS; VALSARTAN;

EID: 84944707049     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/s12882-015-0162-x     Document Type: Article

References (47)

1. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9:S16-23.
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112-9.
3. Sarnak MJ, Levey AS. Epidemiology of Cardiac Disease in Dialysis Patients. Semin Dial. 1999;12:69-76.
4. Himmelfarb J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial. 2009;22:636-43.
5. Gamboa JL, Pretorius M, Todd-Tzanetos DR, Luther JM, Yu C, Ikizler TA, et al. Comparative Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin-Receptor Blockade on Inflammation during Hemodialysis. J Am Soc Nephrol. 2012;23:334-42.
6. Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM, et al. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol. 2002;58:190-7.
7. Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int. 2001;59:1960-6.
8. Stenvinkel P. Interactions between inflammation, oxidative stress, and endothelial dysfunction in end-stage renal disease. J Ren Nutr. 2003;13:144-8.
9. Zoccali C, Bode-Böger SM, Mallamaci F, Benedetto FA, Tripepi G, Malatino LS, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358:2113-7.
10. Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Salvatore Malatino L, et al. Asymmetric Dimethylarginine, C-Reactive Protein, and Carotid Intima-Media Thickness in End-Stage Renal Disease. J Am Soc Nephrol. 2002;13:490-6.
11. Leone A, Moncada S, Vallance P, Calver A, Collier J. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-5.
12. Closs EI, Basha FZ, Habermeier A, Förstermann U. Interference of L-Arginine Analogues with L-Arginine Transport Mediated by the y + Carrier hCAT-2B. Nitric Oxide. 1997;1:65-73.
13. Schwedhelm E, Boger RH. The role of asymmetric and symmetric dimethylarginines in renal disease. Nat Rev Nephrol. 2011;7:275-85.
14. Pope AJ, Karuppiah K, Cardounel AJ. Role of the PRMTÇôDDAHÇôADMA axis in the regulation of endothelial nitric oxide production. Pharmacol Res. 2009;60:461-5.
15. Rodionov RN, Jarzebska N, Weiss N, Lentz SR. AGXT2: a promiscuous aminotransferase. Trends Pharmacol Sci. 2014;35:575-82.
16. Anderstam B, Katzarski K, Bergström J. Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol. 1997;8:1437-42.
17. Veresh Z, Racz A, Lotz G, Koller A. ADMA Impairs Nitric Oxide-Mediated Arteriolar Function Due to Increased Superoxide Production by Angiotensin II-NAD(P)H Oxidase Pathway. Hypertension. 2008;52:960-6.
18. Luo Z, Teerlink T, Griendling K, Aslam S, Welch WJ, Wilcox CS. Angiotensin II and NADPH Oxidase Increase ADMA in Vascular Smooth Muscle Cells. Hypertension. 2010;56:498-504.
19. Ito A, Egashira K, Narishige T, Muramatsu K, Takeshita A. Renin-Angiotensin System is Involved in the Mechanism of Increased Serum Asymmetric Dimethylarginine in Essential Hypertension. Jpn Circ J. 2001;65:775-8.
20. Abbott K, Trespalacios F, Agodoa L, Ahuja T. HIVAN and medication use in chronic dialysis patients in the United States: analysis of the USRDS DMMS Wave 2 study. BMC Nephrol. 2003;4:5.
21. Napoli C, Sica V, de Nigris F, Pignalosa O, Condorelli M, Ignarro LJ, et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J. 2004;148:172.
22. Willoughby SR, Rajendran S, Chan WP, Procter N, Leslie S, Liberts EA, et al. Ramipril Sensitizes Platelets to Nitric Oxide: Implications for Therapy in High-Risk Patients. J Am Coll Cardiol. 2012;60:887-94.
23. Jones B, Kenward MG. Design and Analysis of Crossover Trials. 2nd ed. Boca Raton: CRC Press LLC; 2003.
24. de Jong S, Teerlink T. Analysis of asymmetric dimethylarginine in plasma by HPLC using a monolithic column. Anal Biochem. 2006;353:287-9.
25. Milne GL, Sanchez SC, Musiek ES, Morrow JD. Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protocols. 2007;2:221-6.
26. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A. 1990;87:9383-7.
27. Billings FT, Balaguer JM, Yu C, Wright P, Petracek MR, Byrne JG, et al. Comparative Effects of Angiotensin Receptor Blockade and ACE Inhibition on the Fibrinolytic and Inflammatory Responses to Cardiopulmonary Bypass. Clin Pharmacol Ther. 2012;91:1065-73.
28. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 2002;62:339-45.
29. Kumagai H, Sakurai M, Takita T, Maruyama Y, Uno S, Ikegaya N, et al. Association of Homocysteine and Asymmetric Dimethylarginine With Atherosclerosis and Cardiovascular Events in Maintenance Hemodialysis Patients. Am J Kidney Dis. 2006;48:797-805.
30. Bode-Böger SM, Scalera F, Ignarro LJ. The l-arginine paradox: Importance of the l-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther. 2007;114:295-306.
31. Notsu Y, Yano S, Shibata H, Nagai A, Nabika T. Plasma arginine/ADMA ratio as a sensitive risk marker for atherosclerosis: Shimane CoHRE study. Atherosclerosis. 2015;239:61-6.
32. Pizzarelli F, Maas R, Dattolo P, Tripepi G, Michelassi S, D'Arrigo G, et al. Asymmetric dimethylarginine predicts survival in the elderly. Age. 2013;35:2465-75.
33. Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, et al. Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the Community. Circulation. 2009;119:1592-600.
34. Davignon J, Ganz P. Role of Endothelial Dysfunction in Atherosclerosis. Circulation. 2004;109:27-32.
35. Young CN, Fisher JP, Gallagher KM, Whaley-Connell A, Chaudhary K, Victor RG, et al. Inhibition of nitric oxide synthase evokes central sympatho-excitation in healthy humans. J Physiol. 2009;587:4977-86.
36. Mallamaci F, Tripepi G, Maas R, Malatino L, Böger R, Zoccali C. Analysis of the Relationship between Norepinephrine and Asymmetric Dimethyl Arginine Levels among Patients with End-Stage Renal Disease. J Am Soc Nephrol. 2004;15:435-41.
37. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-8.
38. Pagano PJ, Chanock SJ, Siwik DA, Colucci WS, Clark JK. Angiotensin II Induces p67phox mRNA Expression and NADPH Oxidase Superoxide Generation in Rabbit Aortic Adventitial Fibroblasts. Hypertension. 1998;32:331-7.
39. Aslam S, Santha T, Leone A, Wilcox C. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int. 2006;70:2109-15.
40. Osanai T, Saitoh M, Sasaki S, Tomita H, Matsunaga T, Okumura K. Effect of Shear Stress on Asymmetric Dimethylarginine Release From Vascular Endothelial Cells. Hypertension. 2003;42:985-90.
41. Swartz SL, Williams GH, Hollenberg NK, Levine L, Dluhy RG, Moore TJ. Captopril-induced Changes in Prostaglandin Production: Relationship to Vascular Responses in Normal Man. J Clin Invest. 1980;65:1257-64.
42. Larsen BT, Bubolz AH, Mendoza SA, Pritchard Jr KA, Gutterman DD. Bradykinin-induced dilation of human coronary arterioles requires NADPH oxidase-derived reactive oxygen species. Arterioscler Thromb Vasc Biol. 2009;29:739-45.
43. Wilcox CS. Asymmetric Dimethylarginine and Reactive Oxygen Species: Unwelcome Twin Visitors to the Cardiovascular and Kidney Disease Tables. Hypertension. 2012;59:375-81.
44. Tripepi G, Raso FM, Sijbrands E, Seck MS, Maas R, Boger R, et al. Inflammation and Asymmetric Dimethylarginine for Predicting Death and Cardiovascular Events in ESRD Patients. Clin J Am Soc Nephrol. 2011;6:1714-21.
45. Chan KE, Ikizler TA, Gamboa JL, Yu C, Hakim RM, Brown NJ. Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int. 2011;80:978-85.
46. Grooteman MP, Wauters IM, Teerlink T, Twisk JW, Nube MJ. Plasma dimethylarginine levels in chronic hemodialysis patients are independent of the type of dialyzer applied. Blood Purif. 2007;25:281-9.
47. Busch M, Fleck C, Wolf G, Stein G. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease-possible candidates for paradoxical epidemiology? Amino Acids. 2006;30:225-32.